Driehaus Capital IRWD Position
ExitedDriehaus Capital exited their position in Ironwood Pharmaceuticals Inc. (IRWD) in Q2 2024, after holding the stock for 5 quarters.
The position was first reported in Q2 2023 and has been tracked across 5 quarterly 13F filings.
1 other tracked fund also holds IRWD.
Short interest stands at 12.7% of float with 4.5 days to cover, indicating significant bearish positioning against the stock.
About Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Full company profile →Short Interest
12.7%
4.5 days to cover
Driehaus Capital IRWD Position History
Frequently Asked Questions
Does Driehaus Capital own IRWD?
No. Driehaus Capital exited their position in Ironwood Pharmaceuticals Inc. (IRWD) in Q2 2024. They previously held the stock for 5 quarters.
How many hedge funds own IRWD?
1 specialist biotech hedge fund currently holds IRWD, including Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy IRWD?
Driehaus Capital's position in IRWD was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's IRWD position increasing or decreasing?
Driehaus Capital completely exited their IRWD position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IRWDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →